A plain language summary of results from the FLAURA2 study: Initial (first-line) osimertinib treatment with or without chemotherapy in patients with untreated EGFR-mutated advanced NSCLC

Planchard D.; Jänne P.A.; Cheng Y.; Yang J.C.-H.; Yanagitani N.; Kim S.-W.; Sugawara S.; Yu Y.; Fan Y.; Geater S.L.; Laktionov K.; Lee C.K.; Valdiviezo N.; Ahmed S.; Maurel J.-M.; Andrasina I.; Goldman J.; Ghiorghiu D.; Rukazenkov Y.; Todd A.; Kobayashi K. · Future Oncology (2025) · DOI: 10.1080/14796694.2025.2463880